PL3858333T3 - Wytwarzanie i przechowywanie liposomalnych preparatów rna odpowiednich do terapii - Google Patents

Wytwarzanie i przechowywanie liposomalnych preparatów rna odpowiednich do terapii

Info

Publication number
PL3858333T3
PL3858333T3 PL21151194.4T PL21151194T PL3858333T3 PL 3858333 T3 PL3858333 T3 PL 3858333T3 PL 21151194 T PL21151194 T PL 21151194T PL 3858333 T3 PL3858333 T3 PL 3858333T3
Authority
PL
Poland
Prior art keywords
therapy
production
storage
preparations suitable
rna preparations
Prior art date
Application number
PL21151194.4T
Other languages
English (en)
Inventor
Heinrich Haas
Sebastian HÖRNER
Isaac Hernan ESPARZA BORQUEZ
Thomas Michael HILLER
Ferdia BATES
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of PL3858333T3 publication Critical patent/PL3858333T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL21151194.4T 2017-10-20 2018-10-18 Wytwarzanie i przechowywanie liposomalnych preparatów rna odpowiednich do terapii PL3858333T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762574965P 2017-10-20 2017-10-20

Publications (1)

Publication Number Publication Date
PL3858333T3 true PL3858333T3 (pl) 2026-03-23

Family

ID=63965663

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21151194.4T PL3858333T3 (pl) 2017-10-20 2018-10-18 Wytwarzanie i przechowywanie liposomalnych preparatów rna odpowiednich do terapii

Country Status (23)

Country Link
US (3) US11395799B2 (pl)
EP (2) EP3697384A1 (pl)
JP (3) JP2021500324A (pl)
KR (2) KR102762217B1 (pl)
CN (3) CN111246845A (pl)
AR (2) AR113782A1 (pl)
AU (2) AU2018350846B2 (pl)
CA (2) CA3078292A1 (pl)
DK (1) DK3858333T3 (pl)
ES (1) ES3062541T3 (pl)
FI (1) FI3858333T3 (pl)
HR (1) HRP20260181T1 (pl)
IL (2) IL327141A (pl)
LT (1) LT3858333T (pl)
MX (3) MX2020003413A (pl)
PL (1) PL3858333T3 (pl)
PT (1) PT3858333T (pl)
RS (1) RS67724B1 (pl)
SG (1) SG11202002579SA (pl)
SI (1) SI3858333T1 (pl)
TW (2) TW202146031A (pl)
WO (1) WO2019077053A1 (pl)
ZA (1) ZA202001675B (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
HRP20260181T1 (hr) 2017-10-20 2026-03-27 BioNTech SE Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju
CN111971066B (zh) * 2018-01-18 2025-03-11 伊泽阿恩埃免疫疗法股份有限公司 脂质纳米颗粒
WO2020200472A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
EP4210864A2 (en) 2020-09-08 2023-07-19 Genentech, Inc. Systems and methods for producing pharmaceutical compositions using peristaltic pumps and dampeners
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體ｒｎａ調配物之製備及儲存
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
CN116669709A (zh) * 2020-11-16 2023-08-29 生物技术公司 包含颗粒和mRNA的药物组合物及其制备和储存的方法
BR112023016897A2 (pt) * 2021-02-23 2023-11-21 Natures Toolbox Inc Encapsulação de nanopartículas lipídicas (lnp) de produtos de mrna
WO2022235847A1 (en) 2021-05-04 2022-11-10 BioNTech SE Technologies for early detection of variants of interest
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
KR20240042414A (ko) 2021-07-29 2024-04-02 비온테크 에스이 흑색종의 치료용 조성물 및 방법
EP4412591A1 (en) 2021-10-06 2024-08-14 leon-nanodrugs GmbH Method for preparing lipid nanoparticles
CN114601747A (zh) * 2022-03-07 2022-06-10 广州市万千粉丝化妆品有限公司 一种催生蛋白及rna具有延长细胞端粒和增殖的核蛋白端粒酶在化妆品中的应用
EP4489744A4 (en) * 2022-03-08 2025-11-05 Mastery Biotech Co Ltd PHARMACEUTICAL COMPOSITION COMPRISING RETINOIC ACID AND A CARBOHYDRATE AND ITS USE
US20250360199A1 (en) 2022-07-07 2025-11-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Immunogens and methods for inducing an immune response
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
CN116083491A (zh) * 2023-01-05 2023-05-09 上海利康瑞生物工程有限公司 一种阳离子转染试剂组合物及应用
EP4694857A1 (en) 2023-04-14 2026-02-18 BioNTech SE Vaccine mixing method, syringe and system
AU2024310564A1 (en) 2023-06-29 2025-11-27 BioNTech SE Modular multiplatform system for mrna drug production
WO2025006385A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Novel malaria vaccine comprising ama1 and ron2 antigens
WO2025040709A1 (en) 2023-08-24 2025-02-27 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
WO2025051381A1 (en) 2023-09-08 2025-03-13 BioNTech SE Methods and compositions for localized expression of administered rna
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025151019A1 (ko) * 2024-01-12 2025-07-17 주식회사 루카에이아이셀 양이온성 리포좀 및 이를 이용한 rna 리포플렉스의 제조방법
TW202617177A (zh) 2024-06-18 2026-05-01 德商拜恩技術股份公司 用於治療黑色素瘤之組合物及方法
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026047148A1 (en) 2024-08-29 2026-03-05 BioNTech SE Minimal polypeptide-encoding rnas
WO2026057626A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having multiple enzymatically active domains
WO2026057625A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having a chap domain with engineered active site
WO2026072393A1 (en) * 2024-09-24 2026-04-02 Serán BioScience, LLC Formulations of spray dried lipid nanoparticles
WO2026068864A1 (en) 2024-09-30 2026-04-02 BioNTech SE Engineered ch1 and cl domains for the prevention of chain mispairing
WO2026082899A2 (en) 2024-10-16 2026-04-23 BioNTech SE Rna for preventing or treating tuberculosis
WO2026119817A1 (en) 2024-12-02 2026-06-11 BioNTech SE Agents and methods for targeted delivery of immune effector cells
WO2026125590A1 (en) 2024-12-13 2026-06-18 BioNTech SE Measuring nucleic acid integrity
WO2026125598A1 (en) 2024-12-13 2026-06-18 BioNTech SE Measuring nucleic acid integrity
WO2026148356A1 (en) 2025-01-06 2026-07-09 BioNTech SE Coronavirus and influenza immunogenic combinations
WO2026150132A1 (en) 2025-01-12 2026-07-16 BioNTech SE Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment
WO2026162682A1 (en) 2025-01-29 2026-08-06 BioNTech SE Compositions for delivery of plasmodium rh5 antigens and related methods
WO2026162552A1 (en) 2025-01-31 2026-08-06 BioNTech SE Agents and methods for targeted delivery to cells

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005373A1 (en) * 1999-07-15 2001-01-25 Inex Pharmaceuticals Corp. Methods and apparatus for preparation of lipid vesicles
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
CA2469491A1 (en) * 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US7008403B1 (en) 2002-07-19 2006-03-07 Cognitive Ventures Corporation Infusion pump and method for use
PL1633327T3 (pl) * 2003-06-04 2011-02-28 Univ Georgetown Sposób poprawienia stabilności i okresu trwałości kompleksów liposomowych
EP1512393A1 (de) * 2003-09-08 2005-03-09 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen
CA2649630C (en) * 2006-04-20 2016-04-05 Silence Therapeutics Ag Lipoplex formulations for specific delivery to vascular endothelium
KR20090094148A (ko) * 2006-12-20 2009-09-03 제이-씨 헬쓰 케어 리미티드 페길화 리포좀 독소루비신의 투여 방법
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009111088A2 (en) * 2008-01-02 2009-09-11 The Johns Hopkins University Antitumor immunization by liposomal delivery of vaccine to the spleen
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
RU2573409C2 (ru) * 2009-11-04 2016-01-20 Дзе Юниверсити Оф Бритиш Коламбиа Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3391877A1 (en) * 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
CN102144973A (zh) 2011-03-31 2011-08-10 中国药科大学 一种优化的siRNA阳离子脂质体的处方组成
CN102727436A (zh) 2011-04-15 2012-10-17 百奥迈科生物技术有限公司 核酸脂质体药物制剂
CA2853689C (en) 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2830593B1 (en) 2012-03-26 2019-02-27 BioNTech RNA Pharmaceuticals GmbH Rna formulation for immunotherapy
CN103194489B (zh) * 2013-03-26 2015-09-30 中国科学院过程工程研究所 新型阳离子脂质体核酸类药物制剂,及其制备方法和应用
BR112016000889A2 (pt) * 2013-08-21 2017-12-12 Curevac Ag composição e vacina para tratamento de câncer de próstata
EP3049065A1 (en) * 2013-09-26 2016-08-03 BioNTech AG Particles comprising a shell with rna
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016056398A1 (ja) * 2014-10-06 2016-04-14 ソニー株式会社 画像処理装置および方法
WO2016138175A1 (en) * 2015-02-24 2016-09-01 The University Of British Columbia Continuous flow microfluidic system
EP3271057B1 (en) * 2015-03-19 2019-09-04 The University of Connecticut Systems and methods for continuous manufacturing of liposomal drug formulations
WO2016155809A1 (en) * 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
US20180153822A1 (en) * 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
HRP20260181T1 (hr) 2017-10-20 2026-03-27 BioNTech SE Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju

Also Published As

Publication number Publication date
AR113782A1 (es) 2020-06-10
FI3858333T3 (fi) 2026-01-28
TW202146031A (zh) 2021-12-16
KR102762217B1 (ko) 2025-02-07
AU2023201185A1 (en) 2023-04-06
EP3697384A1 (en) 2020-08-26
CN114392233A (zh) 2022-04-26
ES3062541T3 (en) 2026-04-13
MX2024001210A (es) 2024-11-08
EP3858333A1 (en) 2021-08-04
CA3078292A1 (en) 2019-04-25
BR112020007470A2 (pt) 2020-10-27
US20250108008A1 (en) 2025-04-03
SI3858333T1 (sl) 2026-04-30
IL273852B1 (en) 2026-04-01
KR20200100619A (ko) 2020-08-26
WO2019077053A1 (en) 2019-04-25
MX2024001218A (es) 2024-02-12
KR20250024524A (ko) 2025-02-18
RU2022103533A (ru) 2022-03-10
CA3316345A1 (en) 2026-08-05
US20210161818A1 (en) 2021-06-03
DK3858333T3 (da) 2026-02-23
IL273852B2 (en) 2026-08-01
JP2021500324A (ja) 2021-01-07
MX2020003413A (es) 2020-07-20
IL327141A (en) 2026-05-01
RS67724B1 (sr) 2026-03-31
LT3858333T (lt) 2026-02-25
RU2020113577A3 (pl) 2022-02-16
AR127361A2 (es) 2024-01-17
AU2018350846A1 (en) 2020-04-23
US11395799B2 (en) 2022-07-26
JP2025003984A (ja) 2025-01-14
IL273852A (en) 2020-05-31
RU2020113577A (ru) 2021-11-22
US12059498B2 (en) 2024-08-13
PT3858333T (pt) 2026-02-12
AU2023201185B2 (en) 2025-05-08
TW201927288A (zh) 2019-07-16
AU2018350846B2 (en) 2022-12-08
EP3858333B1 (en) 2025-11-26
HRP20260181T1 (hr) 2026-03-27
JP2023052184A (ja) 2023-04-11
CN114344486A (zh) 2022-04-15
ZA202001675B (en) 2021-07-28
JP7860909B2 (ja) 2026-05-18
SG11202002579SA (en) 2020-05-28
US20200246267A1 (en) 2020-08-06
CN111246845A (zh) 2020-06-05

Similar Documents

Publication Publication Date Title
IL273852A (en) Preparation and storage of liposomal RNA formulations suitable for treatment
IL282352B (en) Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
IL255269A (en) Compositions of obeticholic acid and methods of use
IL268788A (en) Compositions and methods for enhanced gene expression
IL282372A (en) Haploid induction compositions and methods for use therefor
IL269150A (en) Compositions and methods for treating cancer
IL262301A (en) Liposomal preparation and methods of treatment
IL256652A (en) Therapeutic compositions, combinations, and methods of use
IL258955A (en) Compositions and methods for treatment of cancer
IL268814A (en) Compositions and methods for treatment of cancer
IL263224A (en) Methods and compositions for treating cancers
IL289099A (en) Methods for the storage of whole blood, and compositions thereof
IL257486A (en) Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
IL282747A (en) Compositions and methods for inhibiting expression of the alas1 gene
EP3328399A4 (en) Modified cells and methods of therapy
IL268872A (en) Methods and compositions for treating cancers using antisense
PL3349599T3 (pl) Wziewne preparaty nikotyny oraz sposoby ich wytwarzania i zastosowania
IL259204B (en) Compositions and methods of manufacturing protein microparticles
IL242394B (en) Cenicriviroc compositions and methods of making and using the same
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
CL2018001724A1 (es) Terapia combinada de inhibidores de proteinas extra-terminales y bromodominio
IL262459A (en) Compositions and methods for enhanced gene expression of pklr
IL254833B (en) Compositions and methods for active surveillance of prostate cancer
IL269550A (en) Compositions and methods for treating synucleinopathies